CN114846008A - 具有果糖激酶(khk)抑制作用的嘧啶类化合物 - Google Patents

具有果糖激酶(khk)抑制作用的嘧啶类化合物 Download PDF

Info

Publication number
CN114846008A
CN114846008A CN202080090142.5A CN202080090142A CN114846008A CN 114846008 A CN114846008 A CN 114846008A CN 202080090142 A CN202080090142 A CN 202080090142A CN 114846008 A CN114846008 A CN 114846008A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
ring
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090142.5A
Other languages
English (en)
Inventor
潘志祥
贺海鹰
江志赶
夏建华
张蕾
张臣
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Publication of CN114846008A publication Critical patent/CN114846008A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

本发明公开了一类具有KHK抑制作用的化合物或其药学上可接受的盐，及其在制备KHK激酶异常表达相关疾病的药物中的应用。具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080090142.5A 2019-12-25 2020-12-25 具有果糖激酶(khk)抑制作用的嘧啶类化合物 Pending CN114846008A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2019113588387 2019-12-25
CN201911358838 2019-12-25
CN202010042678 2020-01-15
CN2020100426781 2020-01-15
CN2020102368776 2020-03-30
CN202010236877 2020-03-30
CN202010365947 2020-04-30
CN2020103659478 2020-04-30
CN202011051355 2020-09-29
CN2020110513555 2020-09-29
PCT/CN2020/139508 WO2021129817A1 (zh) 2019-12-25 2020-12-25 具有果糖激酶(khk)抑制作用的嘧啶类化合物

Publications (1)

Publication Number Publication Date
CN114846008A true CN114846008A (zh) 2022-08-02

Family

ID=76574858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090142.5A Pending CN114846008A (zh) 2019-12-25 2020-12-25 具有果糖激酶(khk)抑制作用的嘧啶类化合物

Country Status (2)

Country Link
CN (1) CN114846008A (zh)
WO (1) WO2021129817A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116635377A (zh) * 2020-12-25 2023-08-22 四川海思科制药有限公司 己酮糖激酶抑制剂及其用途
WO2023151473A1 (zh) * 2022-02-09 2023-08-17 上海研健新药研发有限公司 一种khk抑制剂，其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN114008036A (zh) * 2019-06-17 2022-02-01 伊莱利利公司 作为己酮糖激酶抑制剂的二取代的吡唑化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN114008036A (zh) * 2019-06-17 2022-02-01 伊莱利利公司 作为己酮糖激酶抑制剂的二取代的吡唑化合物

Also Published As

Publication number Publication date
WO2021129817A1 (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7461499B2 (ja) オクタヒドロピラジノジアザナフチリジンジオン化合物
CN112689638B (zh) 作为lsd1抑制剂的环丙胺类化合物及其应用
CN114846008A (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
CN112672994B (zh) 作为lsd1抑制剂的杂螺环类化合物及其应用
CN114846009B (zh) 具有khk抑制作用的化合物
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
US20230348441A1 (en) Bicyclic compound that acts as crbn protein regulator
CN109071418A (zh) 氨基酸衍生物的前药
CN114502561B (zh) Lsd1抑制剂
JP2022505756A (ja) Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
TW202317097A (zh) 戊二醯亞胺類化合物與其應用
CN114450289B (zh) 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物
JP2021510164A (ja) Ｃｘｃｒ２アンタゴニスト
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
JP2022534316A (ja) Ｃｄｃ７阻害剤としての四環式化合物
TWI814092B (zh) 稠合的三并環衍生物及其在藥學上的應用
CN111592538A (zh) 作为ret抑制剂的脂肪环衍生物
CN117337278A (zh) 烷基羧酸化合物及其应用
CN114787158B (zh) 磺酰脲环取代的单环β-内酰胺类抗生素
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN116615431A (zh) 硼酸类化合物
CN116867791A (zh) 三并环类化合物及其应用
CN114026079A (zh) 一种sglt2/dpp4抑制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination